Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Insight Molecular Diagnostics ( (IMDX) ) just unveiled an announcement.
On September 16, 2025, Insight Molecular Diagnostics Inc. announced that its Board of Directors approved salary increases for key executives. The President and CEO, Joshua Riggs, will see his salary rise from $420,000 to $520,000, while the CFO, Andrea James, will have her salary increased from $341,250 to $441,250, effective September 15, 2025.
The most recent analyst rating on (IMDX) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on Insight Molecular Diagnostics stock, see the IMDX Stock Forecast page.
Spark’s Take on IMDX Stock
According to Spark, TipRanks’ AI Analyst, IMDX is a Neutral.
Insight Molecular Diagnostics’ stock score is primarily influenced by its financial instability, with high debt levels and negative cash flows posing significant risks. While technical indicators show a positive short-term trend, valuation metrics reflect ongoing losses. The earnings call provided some optimism with progress in FDA submissions and assay improvements, but revenue challenges remain a concern.
To see Spark’s full report on IMDX stock, click here.
More about Insight Molecular Diagnostics
Average Trading Volume: 51,944
Technical Sentiment Signal: Hold
Current Market Cap: $94.73M
See more insights into IMDX stock on TipRanks’ Stock Analysis page.